Biocross has appointed Matthew Mittino as its new CEO. Biocross is currently developing several projects centered on the diagnosis of Alzheimer’s disease and the identification of populations at risk of developing the disease.
Over the last 20 years Matthew’s career at Abbott Laboratories in the field of diagnostic, medical, and pharmaceutical products has seen him hold several positions in the United States, Latin America, and Japan. In April 2012 he was appointed as the new CEO of the pharmaceuticals division of Abbot Spain.
Matthew’s appointment to Biocross strengthens its position as a technology company in the field of diagnosis of neurodegenerative diseases. His expertise will contribute greatly to growth and technology transfer at Biocross, and ensure successful market entry for Biocross’ innovative diagnostic systems.
Matthew currently provides operations expertise as a portfolio company CEO, board member, and advisor to VC funds, start-ups, and multinationals.
He holds a BSc in Mechanical Engineering from The University of Notre Dame and an MBA with honors in Marketing and Finance from The University of Chicago Booth.